Key points are not available for this paper at this time.
The human tailless homologue receptor (TLX) is a ligand-activated transcription factor acting as a master regulator of neural stem cell homeostasis. Despite its promising potential in neurodegenerative disease treatment, TLX ligands are rare but required to explore phenotypic effects of TLX modulation and for target validation. We have systematically studied and optimized a TLX agonist scaffold obtained by fragment fusion. Structural modification enabled the development of two TLX agonists endowed with nanomolar potency and binding affinity. Both exhibited favorable chemical tool characteristics including high selectivity and low toxicity. Most notably, the TLX agonists comprise different scaffolds and display high chemical diversity, enabling their use as a set for target identification and validation studies.
Building similarity graph...
Analyzing shared references across papers
Loading...
Emily C. Hank
Ludwig-Maximilians-Universität München
Minh Sai
Ludwig-Maximilians-Universität München
Till Kasch
Ludwig-Maximilians-Universität München
Journal of Medicinal Chemistry
Ludwig-Maximilians-Universität München
Building similarity graph...
Analyzing shared references across papers
Loading...
Hank et al. (Thu,) studied this question.
synapsesocial.com/papers/68e5943fb6db64358752ef7a — DOI: https://doi.org/10.1021/acs.jmedchem.4c01443
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: